Home / Publication / Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

論文

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Author(s): Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain

Year: 2019年9月8日

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

事例紹介

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

ビデオ

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

ビデオ

Meet Floris Fauchet: From Model-Based Drug Development to Martial Arts

ビデオ

Powered by Translations.com GlobalLink Web Software

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

Meet Floris Fauchet: From Model-Based Drug Development to Martial Arts

メルマガ登録

クイックアクセス

ソリューション

お問合せ